Skip to main content
PHAT
NASDAQ Life Sciences

Phathom Q3 Revenue Jumps 71% to $84.7M; Second Straight Quarter of Positive Operating Cash Flow

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$6.65
Mkt Cap
$508.058M
52W Low
$5.015
52W High
$18.31
52W Position info
33% above low
Off High info
64% below high
Rel. Volume info
1.5× avg
Market data snapshot near publication time

PHAT sits 33% above its 52-week low of $5.015.

Summary

Phathom reported Q3 2026 revenue of $84.7M (up 71% year over year), a near-breakeven operating loss, and positive operating cash flow for a second straight quarter, while reaffirming 2026 guidance and saying it needs no new debt or equity financing.


Key Events · Earnings and Guidance · PHAT

  • Q3 Revenue Up 71% to $84.7M

    Net revenues rose $35.2M year over year from $49.5M and 14% sequentially from Q2 2026, with roughly 380,000 VOQUEZNA prescriptions filled in the quarter.

  • Near-Breakeven Quarter, Cash Flow Positive

    Operating loss narrowed to $85 thousand from $15.3M a year ago; non-GAAP adjusted net income was $3.0M versus a $11.2M adjusted loss in Q3 2025, and operating cash flow was positive for a second consecutive quarter.

  • 2026 Guidance Reaffirmed

    Full-year 2026 net revenue guidance held at $310-325M with non-GAAP operating expenses of $235-245M; cash of $184.6M plus expected operating cash flow is stated to cover all debt obligations without new debt or equity.

  • Exclusivity Fight Enters Next Phase

    The D.C. District Court granted Phathom's motion to intervene in BDR's suit against the FDA on October 26, 2026; the FDA comment docket closes November 23, 2026, with NCE exclusivity currently running to May 3, 2032.


Analysis · PHAT · Life Sciences

The commercial ramp is now self-funding: revenue of $84.7M rose 71% year over year and 14% sequentially, operating loss shrank to just $85 thousand from $15.3M a year ago, and the company generated positive operating cash flow for a second consecutive quarter. Management reaffirmed full-year 2026 revenue guidance of $310-325M and explicitly said cash on hand plus expected operating cash flow covers all outstanding debt obligations without new debt or equity — removing the dilution overhang that usually hangs over a company with a $347.6M stockholders' deficit. The main swing factor remains the BDR litigation over VOQUEZNA's NCE exclusivity through May 3, 2032; Phathom was granted intervention on October 26, 2026, and the FDA comment docket closes November 23, 2026. Next hard data point is EoE Phase 2 topline in Q4 2026.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PHAT was trading at $6.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $508.1M. The 52-week trading range was $5.02 to $18.31. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PHAT - Latest Insights

PHAT
Oct 29, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $6.65
Real-time Price: $6.06 info
Change: -$0.590 (-9%) info
Market Cap: $492.627M info
PHAT
Oct 26, 2026, 6:02 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.50
Real-time Price: $6.06 info
Change: +$0.560 (+10%) info
Market Cap: $492.627M info
PHAT
Oct 26, 2026, 4:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $5.50
Real-time Price: $6.06 info
Change: +$0.560 (+10%) info
Market Cap: $492.627M info
PHAT
Oct 23, 2026, 4:00 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $6.86
Real-time Price: $6.06 info
Change: -$0.800 (-12%) info
Market Cap: $492.627M info
PHAT
Sep 29, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $7.30
Real-time Price: $6.06 info
Change: -$1.24 (-17%) info
Market Cap: $492.627M info